Focus Partners Advisor Solutions LLC Acquires Shares of 10,000 Journey Medical Corporation $DERM

Focus Partners Advisor Solutions LLC established a new stake in Journey Medical Corporation (DERM) during the second quarter, acquiring 10,000 shares, while other institutional investors also modified their holdings, bringing institutional ownership to 7.25%. Analyst sentiment is mixed, with a consensus 'Hold' rating and an average price target of $12.17, though some analysts issued 'Buy' ratings with targets up to $13.00. The dermatology-focused pharmaceutical company recently reported Q2 EPS of ($0.16), missing consensus estimates, despite revenue of $15.01 million slightly exceeding projections, indicating continued profitability challenges.

Analysis

Focus Partners Advisor Solutions LLC initiated a new position in Journey Medical Corporation (DERM) during Q2, acquiring 10,000 shares valued at $72,000, contributing to the 7.25% institutional ownership. Other hedge funds, including Pale Fire Capital SE and Jane Street Group LLC, also established new positions in Q1, indicating growing, albeit small, institutional interest in the dermatology-focused pharmaceutical company.

Analyst sentiment for DERM is mixed, with a MarketBeat consensus "Hold" rating and an average price target of $12.17, suggesting potential upside from the current $8.12 opening price. While some analysts like HC Wainwright and Lake Street Capital issued "Buy" ratings with a $13.00 target, Zacks Research upgraded the stock to "Hold," and Wall Street Zen downgraded it to "Hold," reflecting divergent views.

Journey Medical reported Q2 EPS of ($0.16), significantly missing the consensus estimate of ($0.07), despite revenue of $15.01 million slightly exceeding forecasts. The company exhibits substantial profitability challenges, evidenced by a negative net margin of 15.49%, a negative return on equity of 48.69%, and a negative P/E ratio of -21.37. Analysts anticipate a full-year EPS of -1.02, highlighting ongoing unprofitability.

The company maintains a debt-to-equity ratio of 1.11 and a quick ratio of 0.95, suggesting some leverage and potentially tight short-term liquidity. However, the stock is trading above its 50-day ($7.34) and 200-day ($7.20) simple moving averages, indicating recent positive price momentum. With a market capitalization of $213.64 million and a beta of 0.79, DERM appears to be a smaller, less volatile pharmaceutical play.

Key Decisions for Investors

• Investors should closely monitor Journey Medical's future earnings reports for signs of improved profitability, given the significant Q2 EPS miss and negative margins, and assess if the company can achieve positive EPS as anticipated by some analysts.
• Evaluate the divergence in analyst ratings, weighing the consensus 'Hold' against individual 'Buy' recommendations, while acknowledging the current unprofitability and balance sheet leverage (debt-to-equity 1.11, quick ratio 0.95).
• Consider the inherent risks of investing in a small-cap, unprofitable pharmaceutical company, despite recent positive price momentum and growing institutional interest.